Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 8/20 | 0.59 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.49 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.41 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
| ▸ | ACACA | Q13085 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.40 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14831024 | 1.00 | GPR84 (0.59) | GPR84FFAR1FFAR4NFKB1CA2 | |
| SCHEMBL23554231 | 0.85 | GPR84 (0.63) | GPR84FFAR1FFAR4NFKB1CA2 | |
| SCHEMBL15374693 | 0.85 | GPR84 (0.63) | GPR84FFAR1FFAR4NFKB1CA2 | |
| SCHEMBL14830350 | 0.82 | GPR84 (0.59) | GPR84FFAR1FFAR4NFKB1CA2 | |
| SCHEMBL14830349 | 0.82 | GPR84 (0.59) | GPR84FFAR1FFAR4NFKB1CA2 | |
| SCHEMBL29221781 | 0.80 | GPR84 (0.62) | GPR84FFAR1FFAR4FAAH | |
| SCHEMBL8171086 | 0.77 | GPR84 (0.68) | GPR84FFAR1FFAR4NFKB1FAAH | |
| SCHEMBL6800461 | 0.77 | GPR84 (0.68) | GPR84FFAR1FFAR4NFKB1FAAH | |
| SCHEMBL8177703 | 0.77 | GPR84 (0.68) | GPR84FFAR1FFAR4NFKB1FAAH | |
| SCHEMBL8179521 | 0.77 | GPR84 (0.68) | GPR84FFAR1FFAR4NFKB1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140309275-A1 | Sphingosine Analogs, Compositions, and Methods Related Thereto | UNIV EMORY (US) | 2014-10-16 | — | — | US | claimed |
| EP-2760820-A2 | SPHINGOSINE ANALOGS, COMPOSITIONS, AND METHODS RELATED THERETO | Emory University (US) | 2014-08-06 | — | — | EP | claimed |
| WO-2013049280-A2 | SPHINGOSINE ANALOGS, COMPOSITIONS, AND METHODS RELATED THERETO | EMORY UNIVERSITY (US) | 2013-04-04 | — | — | WO | claimed |
| EP-3448392-B1 | ALKYNE CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2026-05-13 | — | — | EP | disclosed |
| US-20260102422-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2026-04-16 | — | — | US | disclosed |
| CN-109689063-B | Alkyne-containing nucleotide and nucleoside therapeutic compositions and related uses thereof | 埃默里大学 | 2026-02-27 | — | — | CN | disclosed |
| US-20260053838-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING SUBSTITUTED NUCLEOTIDES AND NUCLEOSIDES FOR TREATING VIRAL INFECTIONS | UNIV EMORY (US) | 2026-02-26 | — | — | US | disclosed |
| US-12551497-B2 | N4-hydroxycytidine and derivatives and anti-viral uses related thereto | EMORY UNIVERSITY (US) | 2026-02-17 | — | — | US | disclosed |
| WO-2025235664-A1 | PURINE NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2025-11-13 | — | — | WO | disclosed |
| US-12414961-B2 | Substituted nucleosides and nucleotides for treating viral infections | EMORY UNIVERSITY (US) | 2025-09-16 | — | — | US | disclosed |
| US-20250281519-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS, COMBINATIONS AND USES RELATED THERETO | EMORY UNIVERSITY | 2025-09-11 | — | — | US | disclosed |
| WO-2016106050-A1 | N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTI-VIRAL USES RELATED THERETO | EMORY UNIVERSITY (US) | 2016-06-30 | — | — | WO | disclosed |
| WO-2015038596-A1 | NUCLEOTIDE AND NUCLEOSIDE COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2015-03-19 | — | — | WO | disclosed |
| US-20140309275-A1 | Sphingosine Analogs, Compositions, and Methods Related Thereto | UNIV EMORY (US) | 2014-10-16 | — | — | US | disclosed |
| US-20140309275-A1 | Sphingosine Analogs, Compositions, and Methods Related Thereto | UNIV EMORY (US) | 2014-10-16 | — | — | US | disclosed |
| US-20140309275-A1 | Sphingosine Analogs, Compositions, and Methods Related Thereto | UNIV EMORY (US) | 2014-10-16 | — | — | US | disclosed |
| WO-2014124430-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2014-08-14 | — | — | WO | disclosed |
| EP-2760820-A2 | SPHINGOSINE ANALOGS, COMPOSITIONS, AND METHODS RELATED THERETO | Emory University (US) | 2014-08-06 | — | — | EP | disclosed |
| WO-2013049280-A2 | SPHINGOSINE ANALOGS, COMPOSITIONS, AND METHODS RELATED THERETO | EMORY UNIVERSITY (US) | 2013-04-04 | — | — | WO | disclosed |
| WO-2013049280-A2 | SPHINGOSINE ANALOGS, COMPOSITIONS, AND METHODS RELATED THERETO | EMORY UNIVERSITY (US) | 2013-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260102422-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | SARS1, ITK, SLC43A1 | GPR84 3811/4885FFAR1 482/4885FFAR4 296/4885 |
| US-20260053838-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING SUBSTITUTED NUCLEOTIDES AND NUCLEOSIDES FOR TREATING VIRAL INFECTIONS | DCTD, RNMT, NSUN2 | GPR84 3434/4885FFAR1 903/4885FFAR4 1210/4885 |
| US-20250281519-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS, COMBINATIONS AND USES RELATED THERETO | NTPCR, TYMP, MTAP | GPR84 4043/4885FFAR1 3784/4885FFAR4 3634/4885 |
| US-12551497-B2 | N4-hydroxycytidine and derivatives and anti-viral uses related thereto | NSUN2, MTAP, NSUN3 | GPR84 3841/4885FFAR1 3609/4885FFAR4 4247/4885 |
| US-12414961-B2 | Substituted nucleosides and nucleotides for treating viral infections | PNP, NTPCR, TYMP | GPR84 1625/4885FFAR1 3069/4885FFAR4 2912/4885 |
| US-20140309275-A1 | Sphingosine Analogs, Compositions, and Methods Related Thereto | SPHK1, S1PR1, S1PR2 | GPR84 1521/4885FFAR1 755/4885FFAR4 1594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.